CRISPR-based genetic screens are accelerating biological discovery, but current methods
have inherent limitations. Widely used pooled screens are restricted to simple readouts …

The evolutionary processes that drive universal therapeutic resistance in adult patients with
diffuse glioma remain unclear 1 , 2 . Here we analysed temporally separated DNA-…

Glioblastoma is characterized by widespread genetic and transcriptional heterogeneity, yet
little is known about the role of the epigenome in glioblastoma disease progression. Here, …

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib provides effective treatment for patients
with chronic lymphocytic leukemia (CLL), despite extensive heterogeneity in this disease. To …

Interphase fluorescence in situ hybridization (i‐FISH) is a powerful tool for visualizing
various molecular targets in non‐dividing cells. Manual scoring of i‐FISH signals is a labor …

The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is inducing durable responses in chronic
lymphocytic leukemia (CLL) patients with refractory/relapsed disease or with TP53 defect, …

Primary central nervous system lymphomas (PCNSL) are aggressive non-Hodgkin
lymphomas affecting the central nervous system (CNS). Although immunophenotyping studies …

Background Treatment on risk adapted intensive pediatric protocols has improved outcome
for teenagers and young adults (TYA) with T‐cell acute lymphoblastic leukemia (T‐ALL). …

Recent advances in molecular technologies enable sensitive and quantitative assessment
of circulating tumor DNA, offering a noninvasive disease monitoring tool for patients with …

The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has revolutionised the therapeutic
landscape of chronic lymphocytic leukaemia (CLL). Acquired mutations emerging at position …